3BBLACKBIOHealthcare Service Provider
3B Blackbio Diagnostics Ltd — Profit & Loss Statement
₹1126.00
-4.20%
3B Blackbio Diagnostics Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.74 Cr | 0.00 | — |
| Tax Rate For Calcs | 0.25 | 0.28 | 0.27 | 0.26 | — |
| Normalized EBITDA | 65.19 Cr | 45.51 Cr | 33.59 Cr | 44.00 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 2.78 Cr | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 2.78 Cr | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 47.65 Cr | 32.73 Cr | 25.94 Cr | 32.20 Cr | — |
| Reconciled Depreciation | 1.09 Cr | 1.06 Cr | 0.86 Cr | 0.67 Cr | — |
| Reconciled Cost Of Revenue | 25.65 Cr | 21.84 Cr | 17.92 Cr | 31.62 Cr | — |
| EBITDA | 65.19 Cr | 45.51 Cr | 36.37 Cr | 44.00 Cr | — |
| EBIT | 64.11 Cr | 44.46 Cr | 35.51 Cr | 43.33 Cr | — |
| Net Interest Income | -0.11 Cr | -0.12 Cr | 3.67 Cr | -0.11 Cr | — |
| Interest Expense | 0.11 Cr | 0.12 Cr | 0.20 Cr | 0.11 Cr | — |
| Normalized Income | 47.65 Cr | 32.73 Cr | 23.89 Cr | 32.20 Cr | — |
| Net Income From Continuing And Discontinued Operation | 47.65 Cr | 32.73 Cr | 25.94 Cr | 32.20 Cr | — |
| Total Expenses | 47.45 Cr | 42.20 Cr | 33.21 Cr | 44.22 Cr | — |
| Diluted NI Availto Com Stockholders | 47.65 Cr | 32.73 Cr | 25.94 Cr | 32.20 Cr | — |
| Net Income Common Stockholders | 47.65 Cr | 32.73 Cr | 25.94 Cr | 32.20 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 47.65 Cr | 32.73 Cr | 25.94 Cr | 32.20 Cr | — |
| Minority Interests | -0.04 Cr | 0.63 Cr | 0.14 Cr | -4.00 Cr | — |
| Net Income Including Noncontrolling Interests | 47.69 Cr | 32.10 Cr | 25.94 Cr | 32.20 Cr | — |
| Net Income Continuous Operations | 47.69 Cr | 32.10 Cr | 25.94 Cr | 32.20 Cr | — |
| Tax Provision | 16.31 Cr | 12.23 Cr | 9.37 Cr | 11.02 Cr | — |
| Pretax Income | 64.00 Cr | 44.33 Cr | 35.31 Cr | 43.22 Cr | — |
| Other Non Operating Income Expenses | 15.08 Cr | 12.53 Cr | 0.02 Cr | 6.90 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | -0.11 Cr | -0.12 Cr | 3.67 Cr | -0.11 Cr | — |
| Interest Expense Non Operating | 0.11 Cr | 0.12 Cr | 0.20 Cr | 0.11 Cr | — |
| Operating Income | 49.02 Cr | 31.92 Cr | 28.63 Cr | 36.43 Cr | — |
| Operating Expense | 21.80 Cr | 20.36 Cr | 15.28 Cr | 12.60 Cr | — |
| Other Operating Expenses | 13.39 Cr | 12.80 Cr | 6.63 Cr | 5.93 Cr | — |
| Depreciation And Amortization In Income Statement | 1.09 Cr | 1.06 Cr | 0.86 Cr | 0.67 Cr | — |
| Depreciation Income Statement | 1.09 Cr | 1.06 Cr | 0.86 Cr | 0.67 Cr | — |
| Gross Profit | 70.82 Cr | 52.28 Cr | 43.91 Cr | 49.02 Cr | — |
| Cost Of Revenue | 25.65 Cr | 21.84 Cr | 17.92 Cr | 31.62 Cr | — |
| Total Revenue | 96.47 Cr | 74.12 Cr | 61.84 Cr | 80.65 Cr | — |
| Operating Revenue | 96.47 Cr | 74.12 Cr | 61.84 Cr | 80.65 Cr | — |
| Interest Income | — | 6.33 Cr | 3.87 Cr | — | — |
| Rent Expense Supplemental | — | 0.60 Cr | 0.37 Cr | 0.02 Cr | 0.03 Cr |
| Diluted Average Shares | — | 0.87 Cr | 0.86 Cr | 0.75 Cr | 0.75 Cr |
| Basic Average Shares | — | 0.87 Cr | 0.86 Cr | 0.75 Cr | 0.75 Cr |
| Diluted EPS | — | 37.46 | 30.27 | 43.40 | 151.66 |
| Basic EPS | — | 37.46 | 30.27 | 43.40 | 151.66 |
| Other Special Charges | — | -0.01 Cr | — | — | — |
| Write Off | — | -4000.00 | 0.00 | — | — |
| Interest Income Non Operating | — | 6.33 Cr | 3.87 Cr | — | — |
| Research And Development | — | 0.70 Cr | 0.84 Cr | 0.36 Cr | 0.25 Cr |
| Selling General And Administration | — | 0.99 Cr | 1.55 Cr | 0.81 Cr | 0.73 Cr |
| Selling And Marketing Expense | — | 0.46 Cr | 0.37 Cr | 0.47 Cr | 0.44 Cr |
| General And Administrative Expense | — | 0.53 Cr | 1.18 Cr | 0.35 Cr | 0.29 Cr |
| Rent And Landing Fees | — | 0.60 Cr | 0.37 Cr | 0.02 Cr | 0.03 Cr |
| Net Income Extraordinary | — | — | 0.00 | 0.00 | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on 3B Blackbio Diagnostics Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.